Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Gazala Naaz Khan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6396-9511; OpenAlex author ID A5062381283, A5135275483. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 2, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper, 1 trial · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 11

  1. Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. First author DOI 10.1080/14796694.2026.2664776↗
  2. MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon. Co-author DOI 10.3389/fonc.2024.1387535↗
  3. Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12051065↗
  4. Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Co-author DOI 10.1016/j.omto.2020.11.006↗
  5. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. Co-author DOI 10.3389/fonc.2021.678070↗
  6. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Last author DOI 10.1097/coc.0000000000000688↗
  7. Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma. First author DOI 10.12659/ajcr.923803↗
  8. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Co-author DOI 10.1038/srep10867↗
  9. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-1269↗
  10. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiati… Co-author DOI 10.1016/j.ijrobp.2012.11.020↗
  11. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pa… Co-author DOI 10.1016/j.ijrobp.2012.02.051↗

Trials 1

  1. Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer Principal investigator NCT02243358↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Kwon · 3 shared papers, 2020–2024 · strength 0.49
  2. Maen Abdelrahim · 2 shared papers, 2021–2026 · strength 0.40
  3. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.28
  4. Andrea J. Bullock · 1 shared paper, 2026 · strength 0.28
  5. Hassan A. Hatoum · 1 shared paper, 2026 · strength 0.28
  6. Farshid Dayyani · 1 shared paper, 2026 · strength 0.28
  7. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.28
  8. Jitender Monga · 1 shared paper, 2024 · strength 0.26
  9. Shyam Nyati · 1 shared paper, 2024 · strength 0.26
  10. Aseem Rai Bhatnagar · 1 shared paper, 2024 · strength 0.26
  11. Jagadananda Ghosh · 1 shared paper, 2024 · strength 0.26
  12. Neha Patil · 1 shared paper, 2020 · strength 0.24
  13. Mark M. Zalupski · 4 shared papers, 2012–2015 · strength 0.15
  14. Kenneth N. Barton · 1 shared paper, 2021 · strength 0.12
  15. Munther Ajlouni · 1 shared paper, 2021 · strength 0.12
  16. Paul C. Cockrum · 1 shared paper, 2021 · strength 0.12
  17. Amber Draper · 1 shared paper, 2021 · strength 0.12
  18. Andrew Eugene Hendifar · 1 shared paper, 2021 · strength 0.12
  19. Ethan Alexander Burns · 1 shared paper, 2021 · strength 0.12
  20. Olatunji Boladale Alese · 1 shared paper, 2021 · strength 0.12
  21. Nathan Bahary · 1 shared paper, 2021 · strength 0.12
  22. Kenneth H. Yu · 1 shared paper, 2021 · strength 0.12
  23. Edgar Ben‐Josef · 3 shared papers, 2012–2015 · strength 0.11
  24. Kannan Thanikachalam · 1 shared paper, 2020 · strength 0.11
  25. Diane M. Simeone · 2 shared papers, 2012–2014 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.